Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation

Area of Science:

• Pulmonary Medicine
• Biomarker Discovery
• Clinical Translation

Background:

• Chronic obstructive pulmonary disease (COPD) significantly contributes to global morbidity and mortality.
• Current diagnostic and management strategies for COPD exacerbations lack objective biomarkers.
• Existing biomarkers fail to guide therapy, risk stratify patients, or monitor disease activity and progression.

Purpose of the Study:

• To outline the challenges hindering the clinical translation of COPD biomarkers.
• To present a developmental pipeline designed to overcome these challenges.
• To accelerate the discovery and implementation of novel COPD biomarkers.

Main Methods:

• Review of existing literature on COPD biomarker discovery and clinical translation.
• Analysis of the barriers to implementing biomarkers in clinical practice.
• Proposal of a strategic developmental pipeline for novel COPD biomarkers.

Main Results:

• Significant investment in COPD biomarker research has not translated into widespread clinical application.
• Key challenges include lack of objective diagnostic tools for exacerbations and inability to guide treatment or predict progression.
• A structured developmental pipeline is proposed to facilitate biomarker implementation.

Conclusions:

• Addressing the lack of objective biomarkers in COPD is critical for improving patient outcomes.
• The proposed pipeline aims to bridge the gap between biomarker discovery and clinical utility.
• Successful implementation of novel biomarkers will enhance COPD management and therapeutic development.